NR3C1 (Nuclear Receptor Subfamily 3 Group C Member 1)

Comprehensive in vivo evaluations confirmed the multidimensional chemosensitizing efficacy of MH alongside favorable biosafety. Our findings highlight MH as a promising adjuvant strategy for pancreatic cancer, particularly in GEM-resistant cases, by overcoming chemoresistance through the potentiation of ferroptosis.

Our study identifies GR signaling as a tumor-intrinsic immunosuppressive axis in TNBC, transcriptionally activating PD-L1 while repressing MHC-I to drive immune escape. These findings propose GR-targeted therapy combined with immunotherapy as a clinically actionable strategy to reverse immune evasion.

This combination approach was found to be synergistic, resulting in decreased glutathione (GSH) levels and increased DNA damage compared to cisplatin alone. In summary, nitroxide-based hybrids exhibit potent anti-proliferative effects and potentiate cisplatin efficacy through ROS-mediated mechanisms, offering a promising targeted strategy for cervical cancer treatment.

These findings highlight the potential of RSV as a therapeutic agent to overcome corticosteroid resistance in COPD. While our exploratory analyses suggest that RSV may have broader protective effects, including reducing myocardial hypertrophy and preventing skeletal muscle atrophy in emphysema mice, these findings are preliminary and require further investigation to elucidate the underlying mechanisms and their clinical implications.

miR-876-3p could reverse the functions of HOXC-AS1 for HCC cells by targeting NR3C1. Upregulation of HOXC-AS1 promotes HCC progression through the miR-876-3p/NR3C1 axis.

Taken together, this study indicates that PP902 inhibits MAFbx and MuRF1 expression associated with inhibiting FoxO1 in C2C12 cells, potentially useful for developing anti-atrophy functional foods.

Rat pups received lipopolysaccharide (LPS) on postnatal Day 1 (P1), followed by tapering doses of dexamethasone (Dex) or hydrocortisone (HC) from P2 to P4. GR mRNA was significantly reduced in cortex, striatum, hippocampus, and cerebellum in LPS-HC group, with MR mRNA reduction limited primarily to the striatum. LPS sensitized the immature brain to Dex or HC-related cell death to possible apoptosis and augmented the LPS-induced disruption of synaptic integrity in certain brain regions, potentially via altered GR and MR expression that may modulate corticosteroid receptor signaling.

According to our results, such outstanding improvements were attributed to (i) restoring cellular oxidant balance (GSH, MDA & NO), (ii) curbing NF-κB/TNF-α/MCP-1 inflammatory cascade, (iii) HSP90 inhibition with reduced expression of glucocorticoid receptors (GR), (iv) reduced expression of the endoplasmic reticulum stress sensors (CHOP & PERK), (v) activation of protein degradation pathways that degrade the misfolded GR including proteasomal degradation (20 S proteasome) and autophagy (BECLIN1). In conclusion, the findings in this study provide valuable insights into the therapeutic potential of LUM in protecting against DEX-induced deleterious effects on hepatic and aortic tissue in order to get the optimum therapeutic outcome from DEX.

Two molecular subtypes based on these lncRNAs displayed divergent survival patterns and immune profiles, indicating potential therapeutic implications. Our study presents a novel GR-lncRNA-based prognostic model and molecular subtypes for BC, providing valuable insights into disease heterogeneity and offering potential biomarkers for improved prognostic assessment and personalized therapeutic strategies.

Notably, compound 6a demonstrated only weak cytotoxicity at the millimolar level, particularly against the MCF-7 cell line. Given its strong inhibitory activity toward the hGR enzyme, enhancing the membrane permeability of compound 6a may improve its cellular uptake and potency, thereby supporting its potential as a promising anticancer drug candidate.

High level expression of GR is strongly linked to prostate cancer aggressiveness in uni- and multivariate analysis. GR immunohistochemistry - alone or in combination with other markers - holds great potential to identify patients with a high risk for tumor progression.

The expression levels of GR and FOXO1 or p-FOXO1 were strongly correlated in bladder cancer. Specific GR/FOXO1 and GR/p-FOXO1 expression profiles served as independent predictors of disease recurrence or progression.